Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells

NCT00499577 is registered in ClinicalTrials.gov with University of Maryland Greenebaum Cancer Center as lead sponsor.

NCT NCT00499577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00499577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells
Lead sponsor
University of Maryland Greenebaum Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2006
Completion date
Not reported
Enrollment
56 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm